X

Today's Newsletter

Submitted by admin on Mon, 01/11/2021 - 11:16

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834

Today's Newsletter

Today's Newsletter

Submitted by adenham on Fri, 07/23/2021 - 15:27

Today's Newsletter

07-28-2021

Quickly catch up on the top oncology news stories of the day.

`
FDA Grants Regular Approval to Pembrolizumab/Lenvatinib for Advanced Endometrial Carcinoma

The FDA approves pembrolizumab in combination with lenvatinib for patients with advanced endometrial carcinoma that is not MSI-H or dMMR who have disease progression following...

The ASCO Post
07/22/2021
``
``
Multi-Omic Analyses of the m5C Regulator ALYREF Reveal Its Essential Roles in Hepatocellular Carcinoma

In a pan-cancer tissue analysis that included HCC, study investigators assessed the expression of ALYREF compared to normal tissues using The Cancer Genome Atlas database.

Frontiers in Oncology
07/23/2021
Poorer Survival in CRC With Obesity: Is Chemo Dose Too Low?

Patients with CRC who are also obese have poorer survival than those who are not obese. A new study suggests that they may be receiving a lower cumulative dose of adjuvant CT...

Medscape
07/05/2021
The Prognostic Relevance of HER2+ Gain in Metastatic Breast Cancer in the ChangeHER Trial

This study addresses the question if relevant differences exist between subjects who preserve the HER2 status and those who gain the HER2 positivity when relapsed. 

Scientific Reports
07/02/2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

This phase II cohort from PIVOT-02 study evaluates the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin plus nivolumab in first-line metastatic melanoma.

Journal of Clinical Oncology
07/13/2021
Understanding Tolerance for Imatinib Nonadherence Among CML Patients

New analyses from the ADAGIO study presented at the ASCO 2021 Annual Meeting challenge the tolerance for nonadherence to imatinib among patients with chronic myeloid leukemia.

Oncology Times - Latest Articles
07/05/2021